Background/Aims: Whether the level of long noncoding RNA plasmacytoma variant translocation 1 gene (lncRNA PVT1) expression influences the clinical development and outcome of human cancers has not been thoroughly elucidated to date. Inconsistencies still exist regarding the associations between PVT1 and the clinicopathological features, including patient survival data. Additionally, the regulatory mechanism of PVT1 among human cancers remains unclear. Methods: we conducted a comprehensive inquiry to verify the implication of PVT1 expression in cancer patients by conducting a meta-analysis of 19 selected studies and The Cancer Genome Atlas (TCGA) database to examine the relationship between PVT1 expression and both the prognosis and clinicopathological features of cancer patients using STATA 12.0. In addition, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the potential mRNA target genes of PVT1 gathered from TANRIC and Multi Experiment Matrix (MEM) were performed. Results: The level of PVT1 expression in tumor tissues was higher than in paired non-cancer tissues and was significantly associated with a poorer prognosis in cancer patients. Additionally, overexpression of PVT1 was significantly correlated with histological differentiation, tumor (T) classification, lymph node (N) classification and TNM stages. Furthermore, a total of 462 validated target genes were identified, and the GO and KEGG analyses demonstrated that the validated targets of Gang Chen
Introduction
As the technology of RNA deep sequencing (RNA-seq) is being widely used, there is a deeper appreciation for the transcriptome of organisms. According to the differences in length, non-coding RNA (ncRNA) can commonly be classified into two categories: transcripts less than 200 nucleotides are usually accepted as short/small RNAs including miRNAS, siRNAS, piRNAs and those longer than 200 nucleotides are classified as long non-coding RNAs (lncRNAs) [1] . ncRNA, a class of RNA that does not encode proteins, was thought to be transcription noise or evolutionary junk in the past [2, 3] . However, multiple evidence have suggested that ncRNAs played important roles in a variety of biological processes. LncRNAs act as a regulator of gene expression and are closely associated with the development of many diseases, especially malignant tumors [4] [5] [6] [7] .
The human Plasmacytoma variant translocation 1 gene (PVT1) is an RNA gene homologous to the mouse PVT1 to the lncRNA class. This gene locus was first discovered in mouse plasma in the 1980s, and the strongest evidence for frequent variant translocation was found in plasmacytoma [8, 9] . Around the same time, studies showed that the PVT1 gene locus also underwent a variant translocation in human Burkitt's lymphomas [10, 11] . The PVT1 gene is located on chromosome 8, a recognized cancer risk locus shared with the well-known MYC oncogene_ENREF_12, suggesting that PVT1 is a potential oncogene [12] .
In vitro experiments have demonstrated that PVT1 could promote proliferation, migration and invasion of cancer cells. Studies also observed that the level of PVT1 expression was higher in tumor tissues than in adjacent non-cancerous tissues and correlated with a poor prognosis [13, 14] .
The evidence above revealed that PVT1 was involved in tumor progression. In addition, a previous meta-analysis had shown that the overexpression of PVT1 was significantly correlated with the prognosis and lymph node metastasis of cancers [15] . However, the sample size was limited, and the association of PVT1 with other clinicopathological parameters was not investigated in the study. Accordingly, we reviewed the pertinent literature and searched The Cancer Genome Atlas (TCGA) database to conduct the current study to exploring the clinicopathological and prognostic value of PVT1 in patients with various types of cancer. We also investigated the potential target genes of PVT1 through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, and the possible mechanisms of action of PVT1 in tumor progression are discussed in this article.
Materials and Methods

Meta-analysis
Literature review and selection
We conducted a search of the English and Chinese medical literature in PubMed, ISI Web of Science, EMBASE, Science Direct, Wiley Online Library, WanFang, China National Knowledge Infrastructure (CNKI), and Chinese VIP to identify all publications related to PVT1 in cancer patients. Based on the purpose of the study, the search strategy combined the terms "long non-coding RNA PVT1" OR "PVT1" OR "plasmacytoma variant translocation." We also checked for related comments and references by other means. The closing date of our search was July 4, 2017.
The studies eligible for our meta-analysis were evaluated by two independent investigators (RQ He and MJ Qin) with the same multi-step process. Initially, the titles and abstracts were read to exclude the
Data extraction
The following key information was extracted from all eligible studies: the first author's name, publication year, cancer type, country, sample size, assay method, the criterion for dividing PVT1 into high and low groups, follow-up times, prognostic data, histological differentiation, tumor (T) classification, lymph node (N) classification, metastasis (M) classification and TNM stages. Engauge Digitizer 4.1 (http:// digitizer.sourceforge.net/) and Jayne F Tierney's publication [16] were used to extract the HR and 95% CI indirectly from Kaplan-Meier survival curves if the articles did not provide complete survival data.
Quality assessment
The Newcastle-Ottawa Scale (NOS) [17] was used to evaluate the methodological quality of the selected studies by two investigators (RQ He and MJ Qin) independently. Each study was scored based on the following three part system: (i) selection, 0-4; (ii) comparability section, 0-2; and (iii) outcome section, 0-3. The score was no more than 9 points in total, and a score ≥6 indicated the good quality of the study.
Statistical analysis
The information extracted from eligible studies was analyzed with STATA 12.0 software. The survival data were evaluated by HR and 95%CI; PVT1 overexpression pointed to a poor prognosis if a pooled HR>1 was detected. The odd ratio (OR) and 95%CI were calculated to analyze the association of human cancer with the clinicopathological parameters, which included gender, histological differentiation, tumor (T) classification, lymph node (N) classification, metastasis (M) classification and TNM stages. In addition, we performed subgroup analysis based upon the tumor types and the sources of overall survival data. Cochran's Q test and the I 2 index were used to estimate the potential heterogeneity among the selected studies, P < 0.05 or I 2 > 50% were considered statistically significant. If there was no significant heterogeneity（P＞0.05）, a fixed-effect model was used to calculate the HR values; otherwise, a random-effect model would be adopted. Finally, Begg's test was applied to evaluate the publication bias (a two-sided P < 0.05 was considered to be statistically significant).
Analysis of the level of PVT1 expression in all cancers based upon TCGA data
The level of PVT1 expression and overall survival data in the TCGA database were extracted from the Oncolnc website (http://www.oncolnc.org/) [18] . The experimental data were divided into two groups of high and low median level of PVT1 expression. The Cox proportional hazards model of SPSS 22.0 was used to estimate the influence of PVT1 overexpression on survival. We also obtained the level of PVT1 expression across all tumor samples and paired adjacent normal tissues from FireBrowse (http://firebrowse.org/) and GEPIA (http://gepia.cancerpku.cn/), an interactive web based TCGA database. Bar diagrams of PVT1 expression in cancers were plotted with Microsoft Excel 2003.
GO and KEGG Pathway analysis of the validated target genes of PVT1
We used TANRIC (http://ibl.mdanderson.org/tanric/_design/basic/index.html) [19] based upon the TCGA dataset and Multi Experiment Matrix (http://biit.cs.ut.ee/mem/) based upon the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress/) to determine the potential targets of PVT1 in human cancers. VENNY diagram (https://omictools.com/venny-tool) was used to identify those genesoverlapping the two online platforms. To confirm the most significant processes and signaling pathways of PVT1 in human cancers, Gene ontology (GO) [20] 
Results
Meta-analysis
Literature selection and summary of the study characteristics We conducted a search published studies of the association of PVT1 expression and prognosis of cancer patients (Fig. 1) . A total of 722 potential studies were identified after the primary search, of which 42 studies were considered eligible after title and abstract screening. Next, we examined the full text of the remaining articles. Ultimately, 19 studies (n=2006) were included in our analysis and the main characteristics are shown in Table 1 . The follow-up times ranged between 30 and 147.6 months. All selected studies investigated the association of PVT1 and survival analysis, including overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), relapse-free survival (RFS) or progressionfree survival (PFS); 8 studies explored the association between PVT1 and histological differentiation, 14 for TNM stage, 5 for T classification, 11 for N stage, 7 for M classification and 15 for Gender (shown in Table 2 ).
Correlation of lncRNA PVT1 with the clinicopathological characteristics of the study patients As shown in Table 2 , we discovered that high PVT1 level was remarkably related to histological differentiation (OR =1.63, 95%CI: 1.21-2.19, P=0.001; I2 = 37.6%, and P=0.129) ( (Fig. 6A) . However, no significant association was found for distant metastasis (OR =2.43, 95%CI: 0.96-6.14, P=0.061; I2 =54%, and P=0.042) (Fig. 6B ) and gender (OR = 1.06, 95%CI: 0.84-1.34, P=0.611; I2 = 0.0%, P=0.833) (Fig. 6C) . The above results indicated that tumors with high PVT1 levels appeared to exhibit aggressive biological behavior.
Correlation of lncRNA PVT1 expression and survival
We performed an analysis of the association of PVT1 expression and OS based upon the outcomes of the 19 selected studies and TCGA database, which revealed that overexpression of PVT1 was significantly associated with a poor prognosis. A random-effect model was chosen to combine the HR due to high heterogeneity (I2 =62.5%, P =0.00), the HR for OS was 1.31 (95% CI: 1.19-1.43, P＜0.01) (Fig. 2) . The pooled HR for DFS and RFS were 1.78 (95% CI: 1.45-2.17, P＜0.01, fixed-effect model) with low heterogeneity (I2 =0.0%, P=0.755) and 1.90 (95% CI: 1.31-2.75, P＜0.01, fixed-effect model) with low heterogeneity (I2 =0.0%, P=0.379), respectively (Fig. 4) . Table 2 . Combinations of data evaluating the associations of PVT1 with the clinicopathological characteristics of the study patients
Subgroup analysis
Considering the existence of heterogeneity in the studies, two subgroup analyses were conducted based upon the sources of survival data and the type of tumors. In the subgroup analysis for overall survival, we found that high expression of PVT1 was markedly associated with a worse overall survival in publications (HR =2.03, 95%CI: 1.76-2.35, P＜0.01) and TCGA (HR =1.09, 95%CI: 1.03-1.16, P＜0.01) (Fig. 2) . Because the studies of colorectal cancer, prostate cancer, ovarian cancer, cervical cancer, and esophageal squamous cell carcinoma were Fig. 2 . Meta-analysis of the selected studies and TCGA data estimating the association of PVT1 with the patients' overall survival (OS) (P＜0.01, random effect model). (Fig. 3) .
No heterogeneity was noted among these studies.
Publication bias
Begg's funnel plots were applied to assess the publication bias in our study. No publication bias was found in the studies estimating the associations of PVT1 with clinicopathological features and DFS. With regard to OS, a publication bias was not observed in the group derived from TCGA (P=0.651). However, an asymmetric distribution of Egger's funnel plot appeared in the group of studies (P = 0.01); therefore, Cell
a trim-and-fill method was used to adapt the publication bias. The meta-analysis did not engender conflicting conclusions whether the trim-and-fill method was used or not, suggesting that the results of our study were statistically stable ( Fig. 7-9 ).
TCGA data extraction
Based upon the results obtained from FireBrowse, PVT1 was highly expressed in 25 of the 37 tumor tissues except for the remaining 12 with missing data (Fig. 10) . As shown in Fig. 11 derived from GEPIA, PVT1 was highly expressed in 22 types of cancers and was weakly expressed in 9 tumor tissues.
Function analysis of PVT1-related genes in human tumors
To explore the potential mechanism of action of PVT1 ，a total of 462 target genes were identified with TANRIC and MEM. GO and KEGG analyses were performed. analysis showed that PVT1 may play a pivotal role in cancers via multiple pathways including the GnRH signaling pathway, Cytokine-cytokine receptor interaction pathway, Inflammatory mediator regulation of TRP channels pathway, and Neuroactive ligand-receptor interaction pathway (Tables. 3-4 and Fig. 12-15 ).
Discussion
Numerous studies have shown that a high level of expression of PVT1 was significantly associated with the clinical prognosis and other clinicopathological parameters in cancer patients [22, 23] . Review articles have also summarized the critical role that PVT1 may play in the progression of a wide range of cancers [24, 25] . A meta-analysis by Liu et al. also suggested that the up-regulation of PVT1 predicted lymph node metastasis and a worse OS in 03-1.16) . Simultaneously, subgroup analysis also showed that PVT1 was significantly associated with all types of cancer. PVT1 appears to be a potential biomarker reflecting the progression and prognosis of cancer based upon the results of our study. However, rectum adenocarcinoma (READ), skin cutaneous melanoma (SKCM), and stomach adenocarcinoma (SKAD) in the TCGA dataset were correlated with a good prognosis although the results were not statistically significant; their corresponding HR values were 0.786（95%CI：0.379-1.629, P= 0.517），0.92（95%CI：0.742-1.141, P= 0.449）and 0.912（95%CI：0.702-1.183, P= 0.486）, respectively. We reviewed the relevant studies and found that the high PVT1 level was associated with worse outcomes in gastric cancer and colorectal cancer [22, 26, 30, 33, 36] and that there was no corresponding report for melanoma. The inconsistent results in the TCGA and literature studies in these tumors may be caused by sampling error and publication bias. Additional studies are needed to confirm the association between PVT1 and prognosis in different types of cancer.
In the current meta-analysis, significant heterogeneity was present in the studies with OS (P<0.05) when combining the HR values from publications. Heterogeneity also emerged in the studies of the clinicopathological features, including T classification, lymph node metastasis and M classification (P<0.05). Considering that the presence of heterogeneity may influence the results of the meta-analysis, we have treated the heterogeneity carefully [37] _ ENREF_37 with a random effect model to reduce the effect of heterogeneity on the merged result in our study. A publication bias was also noted in studies with OS data (P=0.01) as The height of the bar represents the median expression of certain tumor types or normal tissues. A, the level of PVT1 expression was higher in tumor than in adjacent normal tissue; B, the level of PVT1 was lower in tumor than in adjacent normal tissue. Cell
shown by Begg's test and funnel plots. Hence, a trim-and-fill method was used to adapt the publication bias and the results were consistent with the previous one which suggested that the results of our study were statistically stable. [31, [38] [39] [40] [41] , The same result was also detected in cell line samples in vitro [34, 42] . In recent years, studies on the mechanism of action of PVT1 in cancer have proliferated, and increasing evidence suggested that PVT1 could affect diverse biological behaviors of multiple tumors. Yan et al. observed that the expression of PVT1 was positively associated to miR-1207-5p, which promoted the breast cancer cell proliferation by targeting STAT6 [43] . Ma et al. revealed that PVT1 was highly expressed in glioma vascular endothelial cells, which increased the expression of Beclin1 and Atg7 by targeting miR-186, thereby promoting cell proliferation, migration and angiogenesis [44] . Lan et al. discovered that PVT1 acts as an endogenous sponge of miR-186-5p to reduce its inhibitory effect on yes-associated protein 1, promoting the tumorigenesis of hepatocellular carcinoma [45] . Although advances were made in the understanding of the role of PVT1 in tumors, its precise molecular mechanisms underlying its function are still unclear. Hence, we collected the validated targeting genes of PVT1 using MEM and TANRIC Platform and performed a comprehensive target gene network analysis. The GO and KEGG pathway analysis demonstrated that PVT1 may play a pivotal role in the human tumors via different pathways, including GnRH signaling pathway, Cytokine-cytokine receptor interaction pathway, Inflammatory mediator regulation of TRP channels pathway and Neuroactive ligand-receptor interaction pathway. The hypothalamic decapeptide gonadotropin-releasing hormone (GnRH), also identified as luteinizing hormone-releasing hormone (LHRH), may play a crucial part in the regulation of mammalian reproduction [46, 47] . GnRH binds to a specific GnRH receptor, a member of the large superfamily of seven transmembrane domain receptors that bind to G-proteins [48, 49] . Studies revealed that GnRH receptors is expressed in breast, ovarian, endometrial and prostate_ENREF_50 cancers and that the proliferation in vitro can be repressed by agonistic or antagonistic analogs in various human cancer cell lines [50] [51] [52] [53] . Our study found that PVT1 is involved in tumor progression by regulating the GnRH pathway. These findings were in agreement with the previous reports that PVT1 increased the proliferation, invasion, and migration in gynecological tumor cells and was associated with poor prognosis [13, 29] . There are several limitations to our study. For the meta-analysis, different cut off values for PVT1 in the selected studies were a factor in yielding Publication bias. Meanwhile, since there were no direct results of multivariate analysis in some eligible studies, we had to extract the relevant data through the Kaplan-Meier Curve, which may lead to a deviation of HR values. Moreover, the diagnostic value of PVT1 in cancers was not evaluated in the current meta-analysis for lack of enough diagnostic data of PVT1 from the literature research. Hence, further study is needed to explore the clinical significance and diagnostic value of PVT1 in human cancers. In addition, although PVT1 can act through various mechanisms, only one possible mechanism for the role of PVT1 in gene regulation was investigated based upon the correlation of gene expression levels between PVT1 and mRNA. For a better understanding of PVT1 functions, further research is warranted to explore other possible mechanisms.
Conclusion
Our study demonstrated that higher PVT1 expression was significantly associated with an aggressive disease course in patients with cancer, predicting a poorer TNM stage, invasion depth, lymph node metastasis, and distant metastasis and shorter OS, DFS, and RFS times. We also demonstrated that PVT1 plays an essential role in biological processes via a variety of pathways. Considering the limitations of the current analysis, further studies are warranted to explore the function of PVT1 and its relationship with cancers. 
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